In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate
Some double-blind, placebo-controlled trials have shown that Azelastine (Aze) high dose (0.15%) was effective in seasonal (SAR) and perennial allergic rhinitis (PAR). However, there was no long-term comparison between Aze 0.15% and intranasal corticosteroids (INCS) on safety and quality of life in p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | World Allergy Organization Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455124001534 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841526272969146368 |
|---|---|
| author | Jean Bousquet, MD Ludger Klimek, MD Hans-Christian Kuhl, PhD Duc Tung Nguyen, MD Rajesh Kumar Ramalingam, MD G. Walter Canonica, MD William E. Berger, MD |
| author_facet | Jean Bousquet, MD Ludger Klimek, MD Hans-Christian Kuhl, PhD Duc Tung Nguyen, MD Rajesh Kumar Ramalingam, MD G. Walter Canonica, MD William E. Berger, MD |
| author_sort | Jean Bousquet, MD |
| collection | DOAJ |
| description | Some double-blind, placebo-controlled trials have shown that Azelastine (Aze) high dose (0.15%) was effective in seasonal (SAR) and perennial allergic rhinitis (PAR). However, there was no long-term comparison between Aze 0.15% and intranasal corticosteroids (INCS) on safety and quality of life in perennial allergic rhinitis.An open-label, active-controlled, parallel-group one-year study comparing mometasone furoate and Aze 0.15% in adults assessed safety over 1 year. Efficacy using the 28-item rhino-conjunctivitis quality of life questionnaire (RQLQ) was a secondary end point.A total of 703 patients were randomized and 687 (97.7%) were included in the intent-to-treat (ITT) population. The present formulation was shown to be safe with long-term use over 12 months, with a mean duration of exposure of 270.7 days.Over the one-year period, there was no significant difference for any RQLQ domains between Aze and mometasone furoate (MF) for all evaluations (baseline, 6, 9, and 12 months). This study suggests that Aze 0.15% and MF display a similar improvement of RQLQ ( 2.80 [2.78] for Aze 0.15% vs 2.81 [2.75] for MF). Clinical trial registry number: NCT00720382. |
| format | Article |
| id | doaj-art-5a8cfd33379a4185a2eaf91fb721b1fe |
| institution | Kabale University |
| issn | 1939-4551 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj-art-5a8cfd33379a4185a2eaf91fb721b1fe2025-01-17T04:49:17ZengElsevierWorld Allergy Organization Journal1939-45512025-01-01181101021In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoateJean Bousquet, MD0Ludger Klimek, MD1Hans-Christian Kuhl, PhD2Duc Tung Nguyen, MD3Rajesh Kumar Ramalingam, MD4G. Walter Canonica, MD5William E. Berger, MD6Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany; Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Corresponding author. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany; Center for Rhinology and Allergology, Wiesbaden, GermanyBiometrics, Meda Pharma GmbH & Co KG (A Viatris Company), Bad-Homburg, GermanyGlobal Clinical Sciences, MEDA Pharma GmbH & Co KG (A Viatris Company), Bad Homburg, GermanyMylan Pharmaceuticals Private Limited (Now Viatris), Bengaluru, IndiaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Milan, ItalyAllergy & Asthma Solutions, Coto de Caza, CA, USASome double-blind, placebo-controlled trials have shown that Azelastine (Aze) high dose (0.15%) was effective in seasonal (SAR) and perennial allergic rhinitis (PAR). However, there was no long-term comparison between Aze 0.15% and intranasal corticosteroids (INCS) on safety and quality of life in perennial allergic rhinitis.An open-label, active-controlled, parallel-group one-year study comparing mometasone furoate and Aze 0.15% in adults assessed safety over 1 year. Efficacy using the 28-item rhino-conjunctivitis quality of life questionnaire (RQLQ) was a secondary end point.A total of 703 patients were randomized and 687 (97.7%) were included in the intent-to-treat (ITT) population. The present formulation was shown to be safe with long-term use over 12 months, with a mean duration of exposure of 270.7 days.Over the one-year period, there was no significant difference for any RQLQ domains between Aze and mometasone furoate (MF) for all evaluations (baseline, 6, 9, and 12 months). This study suggests that Aze 0.15% and MF display a similar improvement of RQLQ ( 2.80 [2.78] for Aze 0.15% vs 2.81 [2.75] for MF). Clinical trial registry number: NCT00720382.http://www.sciencedirect.com/science/article/pii/S1939455124001534Perennial allergic rhinitisAzelastineMometasone furoateRQLQ |
| spellingShingle | Jean Bousquet, MD Ludger Klimek, MD Hans-Christian Kuhl, PhD Duc Tung Nguyen, MD Rajesh Kumar Ramalingam, MD G. Walter Canonica, MD William E. Berger, MD In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate World Allergy Organization Journal Perennial allergic rhinitis Azelastine Mometasone furoate RQLQ |
| title | In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate |
| title_full | In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate |
| title_fullStr | In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate |
| title_full_unstemmed | In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate |
| title_short | In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate |
| title_sort | in perennial allergic rhinitis rqlq is improved similarly by azelastine 0 15 and mometasone furoate |
| topic | Perennial allergic rhinitis Azelastine Mometasone furoate RQLQ |
| url | http://www.sciencedirect.com/science/article/pii/S1939455124001534 |
| work_keys_str_mv | AT jeanbousquetmd inperennialallergicrhinitisrqlqisimprovedsimilarlybyazelastine015andmometasonefuroate AT ludgerklimekmd inperennialallergicrhinitisrqlqisimprovedsimilarlybyazelastine015andmometasonefuroate AT hanschristiankuhlphd inperennialallergicrhinitisrqlqisimprovedsimilarlybyazelastine015andmometasonefuroate AT ductungnguyenmd inperennialallergicrhinitisrqlqisimprovedsimilarlybyazelastine015andmometasonefuroate AT rajeshkumarramalingammd inperennialallergicrhinitisrqlqisimprovedsimilarlybyazelastine015andmometasonefuroate AT gwaltercanonicamd inperennialallergicrhinitisrqlqisimprovedsimilarlybyazelastine015andmometasonefuroate AT williamebergermd inperennialallergicrhinitisrqlqisimprovedsimilarlybyazelastine015andmometasonefuroate |